Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. (Q53324757)
Jump to navigation
Jump to search
scientific article published in June 2001
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. |
scientific article published in June 2001 |
Statements
1 reference
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. (English)
1 reference
P M Fracasso
1 reference
M F Brady
1 reference
D H Moore
1 reference
J L Walker
1 reference
P G Rose
1 reference
L Letvak
1 reference
T M Grogan
1 reference
W P McGuire
1 reference
1 June 2001
1 reference
19
1 reference
2975-2982
1 reference
12
1 reference
Identifiers
1 reference